novik
Cheul H. Cho, Ph.D. Chief Scientific Officer
Dr. Cheul Cho leads HµREL’s research and development functions, and he also serves as the Company’s principal technical liaison to scientists in HµREL’s client organizations. He has played a central role in the development and characterization of HµREL’s Hµrelhuman™ and eight other pre-clinical species co-cultures, and also of the Hµrelflow™ multi-tissue microfluidic platform, of all of which he is an inventor. Dr. Cho has published more than 25 journal articles in tissue engineering, stem cell bioengineering, regenerative medicine, and polymeric biomaterials. He holds 4 patents. Prior to Hurel, he was an assistant professor of Biomedical Engineering at the New Jersey Institute of Technology (NJIT). Before NJIT, he was a postdoctoral researcher in the Center for Engineering in Medicine at Harvard Medical School. Dr. Cho holds a Ph.D. and M.S. in chemical and biomedical engineering from Wayne State University and the University of Iowa, respectively.  
 
HµRELToxTM
multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
HµRELviralTM
Long-enduring infectious liver disease platform
Time-Based
Toxicity Ratios*
A new marker for hepatotoxic chronicity

TAAP
*patent pending
HµRELfluxTM
a new, patent-pending
efflux transport
assay method
DMPK
Superior intrinsic clearance
and biotransformation of
low-turnover drugs

DMD